finnCap have advised Synairgen plc (AIM: SNG), the respiratory drug discovery and development company on their £14m fundraising.

Richard Marsden, CEO of Synairgen said:

” We are delighted with the support for this financing which will enable us to assess SNG001’s effectiveness in COVID-19 patients.  A successful outcome from the trial would be a major breakthrough in the fight against coronavirus and a significant value-enhancing event for Synairgen and our shareholders.  Our wholly-owned drug, SNG001, has already been well tolerated in clinical trials in more than 200 respiratory patients to date and has accelerated lung function recovery in two Phase II asthma trials in patients with a cold or flu infection.

We thank everyone involved for their support, both internally and externally – staff, investigators, regulatory bodies, all our service, product and equipment providers, and our current and new high quality specialist and generalist shareholders – as we strive to help society during this pandemic.”